Moral panic triggered by psychedelics

Moral panic triggered by psychedelics was a mid-1960s upheaval in which LSD came to signify a threat to public order and mental health rather than a possible medical treatment. The alarm grew from genuine adverse reactions and the drug’s movement beyond clinical settings, but it also gathered force through sensational reporting, disputed claims, and collapsing distinctions between research, therapy, and recreational use. By 1966, the resulting political climate had helped shut down nearly all psychedelic research programs in the United States.

A contested treatment model

The backlash had roots in a change within psychiatry itself. In 1956–1957, Humphry Osmond, Al Hubbard, and Aldous Huxley advanced psychedelic therapy: rather than using the drugs to imitate psychosis or assist conventional psychoanalysis, the approach called for a single high-dose session intended to produce a profound, potentially transformative experience. That model challenged established psychiatric practice by asking clinicians to rethink the roles of patient and therapist, and by placing spiritual experience close to the center of treatment.

The approach also made the boundaries of scientific medicine harder to police. As Charles Grob later observed in writing about psychedelic history, psychedelic therapy blurred distinctions between religion and science, illness and health, and healer and sufferer. Its reliance on set and setting—contextual factors outside the drug’s pharmacology—also made it resemble forms of shamanic practice. Meanwhile, the growing status of the double-blind, placebo-controlled trial as the standard for drug testing posed a practical obstacle: the striking effects of psychedelics made them difficult to study without participants and researchers knowing which treatment had been given.

Professional criticism sharpened by 1963. Roy Grinker, editor of the Archives of General Psychiatry, attacked investigators who took the drugs themselves, arguing that their own experiences compromised their competence and conclusions. Yet avoiding personal experience had costs too: psychiatrists unfamiliar with psychedelics could interpret their effects as psychosis rather than as an experience with other possible meanings. The older psychotomimetic interpretation consequently returned with new force. In the preceding decade, Al Hubbard’s Commission for the Study of Creative Imagination had already signaled a widening division between medical and spiritual aims; Sidney Cohen resigned from its board in 1957, as Hubbard increasingly described his aims as lying beyond empirical science.

Risk evidence and public alarm

The dangers were neither wholly imagined nor accurately represented. As bootleg LSD circulated in 1962 and 1963, people experiencing severe reactions began arriving in emergency rooms and psychiatric wards. Some experienced paranoia, mania, catatonia, anxiety, or recurring symptoms days or weeks after taking LSD. Some people at risk of schizophrenia had genuine psychotic episodes, and a difficult experience could trigger one. In other cases, clinicians unfamiliar with psychedelics mistook panic for full-blown psychosis, a response that could worsen the situation. In 1965, Bellevue Hospital in Manhattan admitted sixty-five people for what it classified as LSD-induced psychoses.

Sidney Cohen’s research offers a measure of how the risk picture changed—and how rare balanced assessment became. Beginning in 1960, he surveyed forty-four researchers and gathered information on about five thousand subjects who had taken LSD or mescaline on a total of twenty-five thousand occasions. His first report found only two credible reports of suicide, several temporary panic reactions, and no evidence of serious, prolonged physical side effects in that population. He judged complications surprisingly infrequent when the drugs were administered by qualified therapists and researchers.

Cohen’s later work complicated that early reassurance. In 1962, he reported serious complications and occasional catastrophic reactions associated with casual use outside clinical settings and with irresponsible therapists. He warned of suicide, prolonged psychotic reactions, and harmful conduct. A subsequent paper described psychotic breaks, an attempted suicide, and a boy who experienced visual distortions and anxiety for more than a month after taking a sugar cube containing LSD that his father, a detective, had confiscated. The article prompted Grinker to condemn psychedelic research in an accompanying commentary, although Cohen continued to believe that responsible therapeutic use had potential. In 1966, Cohen reported further casualties, including two accidental deaths: one by drowning and another after a person walked into traffic.

The public story, however, often flattened distinctions among these different circumstances. A widely publicized claim that LSD could damage chromosomes and cause birth defects was later discredited, but its refutation attracted little notice. At the same time, headlines presented individual incidents as evidence of a widening catastrophe, with reports of deaths, blindness, children taking the drug, and LSD use approaching epidemic proportions. Life magazine, which had helped introduce public interest in psychedelics through R. Gordon Wasson’s earlier article on psilocybin, joined the condemnation with a cover story portraying LSD as a threat that had escaped control. Its shift from earlier enthusiasm to alarm captured the reversal in public framing.

From controversy to shutdown

The spread of LSD outside clinical supervision made it harder to preserve a distinction between legitimate research and uncontrolled use. Researchers and journalists alike selected evidence and anecdotes that supported their positions, while emergency-room cases and intense media coverage made the dangers immediate and legible. By the middle of the decade, the dispute was no longer only about the balance of therapeutic benefit and medical risk: it had become a conflict over whether psychedelic experience could be contained by medical, scientific, or religious protocols at all.

That conflict had institutional consequences. In April 1966, Sandoz withdrew LSD-25 from circulation, transferring most of its remaining supplies to the U.S. government. The withdrawal contributed to the closure of many of the seventy research programs then underway. At Senate hearings in May, Timothy Leary and Cohen tried to distinguish legitimate research from the black market. Senator Robert F. Kennedy questioned why projects considered worthwhile six months earlier should no longer be supported, and warned that banning medical use because of illicit use would be a loss to the nation. His intervention did not reverse the course of events. In October, the FDA ordered roughly sixty researchers around the country to stop their work.

The closure reached research in progress at the moment it was being prepared. At the International Foundation for Advanced Study in Menlo Park, James Fadiman had just administered doses to four participants in a problem-solving experiment when the letter revoking FDA approval arrived. The program closed the following day, along with virtually every other psychedelic research program then operating in the United States. The Maryland Psychiatric Research Center at Spring Grove was the major exception: its researchers continued studying LSD and psilocybin until 1976, including for alcoholism, schizophrenia, and the existential distress of cancer patients.

Aftermath and the question of containment

The shutdown did not settle whether psychedelics should be understood principally as dangerous drugs, medical treatments, or experiences requiring a broader social framework. One interpretation of the first research wave is that its competing models—psychotomimetic, psycholytic, psychedelic, and later entheogenic—were attempts to create a suitable container: protocols and theories that could regulate the drugs’ power. The countercultural turn toward unguided, do-it-yourself use rejected the need for such a container. The history presented here treats that rejection as risky, while also recognizing that experimentation was how the risks and possibilities became visible in the first place.

The risks of losing structure appeared again in underground practice. After psychedelics were placed in Schedule I in 1970, Leo Zeff chose to continue his therapeutic work clandestinely. He found that different psychedelics could help patients move past defenses and encounter buried material and spiritual insights, sometimes in a single session. In his practice, guides’ agreements with clients and ceremonial elements helped structure the experience. His example belongs to a later effort to preserve guidance and protocols in the face of prohibition, rather than to the uncontrolled use that had helped intensify public alarm.

The later return of clinical research showed that the public and professional verdict was not permanent. In 2016, studies at New York University and Johns Hopkins University reported clinically significant reductions in anxiety and depression for about 80 percent of their cancer patients, with effects lasting at least six months. The trials were small, involving eighty participants altogether, and required larger studies; nevertheless, the findings drew cautious support from the mental-health community and requests from medical schools to participate in further research. New York University moved Stephen Ross’s treatment room from its dental college into the main hospital, and its cancer center sought a room for a future trial.

Renewed respectability has not ended the argument over who should be able to use psychedelics or in what setting. Bob Jesse cautioned that making medical treatment the sole legitimate path could be a mistake, while Rick Doblin and Katherine MacLean described wider possibilities, from legalization to carefully controlled use beyond treatment of illness. Other researchers emphasized trained guides and support after a session, arguing that an intense spiritual experience does not by itself become a lasting spiritual life. The history of the panic thus leaves two linked questions unresolved: how to respond honestly to real risks, and how to prevent fear of those risks from erasing every form of carefully supported use.